AVN-211, also known as CD-008-0173, is a Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's Disease. AVN-211 showed a similar or better anxiolytic efficacy than fenobam, rufinamide, lorazepam, and buspirone in an elevated plus-maze model, elevated platform, and open field tests. AVN-211 demonstrated low toxicity and no side effects in vivo, an appropriate pharmacokinetic profile, and stability. AVN-211 significantly delayed or partially halted the progressive decline in memory function associated with AD, which makes it an interesting drug candidate for the treatment of neurodegenerative and psychiatric disorders. Advanced clinical trials are currently under active discussion and in high priority.
MedKoo Cat#: 522709
Name: AVN-211
CAS#: 1173103-84-8
Chemical Formula: C15H15N3O2S2
Exact Mass: 333.0606
Molecular Weight: 333.42
Elemental Analysis: C, 54.03; H, 4.53; N, 12.60; O, 9.60; S, 19.23
The following data is based on the product molecular weight 333.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
